ICATIBANT ACETATE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ICATIBANT ACETATE (ICATIBANT ACETATE).
Competitive antagonist of bradykinin B2 receptors, inhibiting bradykinin-mediated vasodilation, increased vascular permeability, and pain signaling. Also inhibits bradykinin-induced release of tissue plasminogen activator.
| Metabolism | Primarily metabolized by hydrolytic enzymes, including aminopeptidases and carboxypeptidases, into inactive metabolites. Not significantly metabolized by CYP450 system. |
| Excretion | Primarily renal: 40% unchanged drug; 40% as inactive metabolites; biliary/fecal <10%. |
| Half-life | Terminal elimination half-life approximately 1-2 hours in healthy adults, supporting intermittent intravenous dosing every 6 hours. |
| Protein binding | Approximately 44% bound to plasma proteins (primarily albumin). |
| Volume of Distribution | Approximately 0.4 L/kg, indicating distribution primarily in extracellular fluid. |
| Bioavailability | Subcutaneous: ~100% (complete absorption). |
| Onset of Action | Intravenous: within 30 minutes; Subcutaneous: within 30-60 minutes. |
| Duration of Action | Clinical effect lasts 4-6 hours, with symptomatic improvement typically sustained for 6-12 hours; repeat dosing may be needed. |
30 mg subcutaneous injection (pre-filled syringe) at the first sign of an acute attack; may repeat every 6 hours as needed, not to exceed 3 doses in 24 hours.
| Dosage form | INJECTABLE |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment (CrCl 30-89 mL/min). For severe renal impairment (CrCl <30 mL/min) or end-stage renal disease, consider using icatibant with caution as data are limited; no specific dose recommendation available. |
| Liver impairment | No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Not studied in severe hepatic impairment (Child-Pugh C); use with caution. |
| Pediatric use | For pediatric patients (age ≥2 years and weight ≥12 kg): 0.4 mg/kg (maximum 30 mg) subcutaneous injection at the first sign of an acute attack; may repeat every 6 hours as needed, not to exceed 3 doses in 24 hours. |
| Geriatric use | No specific dose adjustment recommended for elderly patients (age ≥65 years) based on pharmacokinetic data. Clinical studies included limited numbers of elderly subjects; use with caution due to potential age-related renal or hepatic decline. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for ICATIBANT ACETATE (ICATIBANT ACETATE).
| Breastfeeding | No data on presence in human milk. Icatibant is a peptide and likely degraded in gastrointestinal tract; M/P ratio unknown. Weigh benefits of breastfeeding against potential risk to infant. Consider alternatives. |
| Teratogenic Risk | No adequate and well-controlled studies in pregnant women. In animal studies, icatibant did not produce teratogenic effects at doses up to 32 times the maximum recommended human dose. However, fetal toxicity (reduced fetal weight, delayed ossification) occurred at maternally toxic doses. Risk cannot be ruled out; use only if clearly needed, especially during first trimester. |
■ FDA Black Box Warning
None.
| Serious Effects |
["Hypersensitivity to icatibant or any component of the formulation"]
| Precautions | ["Icatibant is not effective for laryngeal attacks requiring airway protection; monitor for laryngeal edema.","Administration by healthcare professional required for symptomatic treatment.","Potential for hypersensitivity reactions (urticaria, rash, pruritus).","Monitor for worsening or repeat attacks after initial treatment."] |
Loading safety data…
| Fetal Monitoring | Monitor maternal vital signs during administration. No specific fetal monitoring required, but ultrasound for fetal growth may be considered if used in late pregnancy. |
| Fertility Effects | No human data. In animal studies, no impairment of male or female fertility at doses up to 32 mg/kg daily. |